Magdi Salih

Prof. Dr. Magdi Salih

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AAAbdulelah Ahmad Aljuaid
Abdulelah Ahmad Aljuaid
MAMazen Almehmadi
Mazen Almehmadi
AAAhad Amer Alsaiari
Ahad Amer Alsaiari
MAMamdouh Allahyani
Mamdouh Allahyani
OAosama abdulaziz
osama abdulaziz
IKIdrees Khan
Idrees Khan
Industrial effluents containing dyes are the dominant pollutants, making the drinking water unfit. Among the dyes, methylene orange (MO) dye is mutagenic, carcinogenic and toxic to aquatic organisms. Therefore, its removal from water bodies through effective and economical approach is gaining increased attention in the last decades. Photocatalytic degradation has the ability to convert economically complex dye molecules into non-toxic and smaller species via redox reactions, by using photocatalysts. g-C3N4 is a metal-free n-type semiconductor, typical nonmetallic and non-toxici polymeric photocatalyst. It widely used in photocatalytic materials, due to its easy and simple synthesis, fascinating electronic band structure, high stability and abundant availability. As a photocatalyst, its major drawbacks are its limited efficiency in separating photo-excited electron–hole pairs, high separated charge recombination, low specific surface area, and low absorption coefficient. In this review, we report the recent modification strategies adopted for g-C3N4 for the efficient photodegradation of MO dye. The different modification approaches, such as nanocomposites and heterojunctions, as well as doping and defect introductions, are briefly discussed. The mechanism of the photodegradation of MO dye by g-C3N4 and future perspectives are discussed. This review paper will predict strategies for the fabrication of an efficient g-C3N4-based photocatalyst for the photodegradation of MO dye.

1 June 2019 in Saudi Medical Journal
Verified
Journal Article
Open access
MAMazen Almehmadi
Mazen Almehmadi
MSMagdi Salih
Magdi Salih
AAAyman S. Al-Hazmi
Ayman S. Al-Hazmi
Saudi Medical Journal;SMJ;smj;saudi medical journal;saudi medical journals

4 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SHShuaibu Hudu
Shuaibu Hudu
FEFayig Elmigdadi
Fayig Elmigdadi
AQAiman Al Qtaitat
Aiman Al Qtaitat
MAMazen Almehmadi
Mazen Almehmadi
AAAhad Amer Alsaiari
Ahad Amer Alsaiari
Mohd ImranMohd Imran
Mohd Imran
Rett syndrome (RTT) is a rare disability causing female-oriented pediatric neurodevelopmental unmet medical need. RTT was recognized in 1966. However, over the past 56 years, the United States Food and Drug Administration (USFDA) has authorized no effective treatment for RTT. Recently, Trofinetide was approved by the USFDA on 10 March 2023 as the first RTT treatment. This article underlines the pharmaceutical advancement, patent literature, and prospects of Trofinetide. The data for this study were gathered from the PubMed database, authentic websites (Acadia Pharmaceuticals, Neuren Pharmaceuticals, and USFDA), and free patent databases. Trofinetide was first disclosed by Neuren Pharmaceuticals in 2000 as a methyl group containing analog of the naturally occurring neuroprotective tripeptide called glycine-proline-glutamate (GPE). The joint efforts of Acadia Pharmaceuticals and Neuren Pharmaceuticals have developed Trofinetide. The mechanism of action of Trofinetide is not yet well established. However, it is supposed to improve neuronal morphology and synaptic functioning. The patent literature revealed a handful of inventions related to Trofinetide, providing excellent and unexplored broad research possibilities with Trofinetide. The development of innovative Trofinetide-based molecules, combinations of Trofinetide, patient-compliant drug formulations, and precise MECP2-mutation-related personalized medicines are foreseeable. Trofinetide is in clinical trials for some neurodevelopmental disorders (NDDs), including treating Fragile X syndrome (FXS). It is expected that Trofinetide may be approved for treating FXS in the future. The USFDA-approval of Trofinetide is one of the important milestones for RTT therapy and is the beginning of a new era for the therapy of RTT, FXS, autism spectrum disorder (ASD), brain injury, stroke, and other NDDs.

28 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMazen Almehmadi
Mazen Almehmadi
MSMagdi Salih
Magdi Salih
TETariq E. Elmissbah
Tariq E. Elmissbah
AAAbdulaziz Alsharif
Abdulaziz Alsharif
NANaif Alsiwiehri
Naif Alsiwiehri
HDHaytham Dahlawi
Haytham Dahlawi
Objectives: The aim of this study was to estimate the prevalence of anemia among patients newly diagnosed with solid malignancies at King Faisal Hospital in Taif Province, Kingdom of Saudi Arabia. Methods: A descriptive, cross-sectional, hospital-based study was conducted from December 2017 to March 2020. A total of 320 patients newly diagnosed with solid malignancy were examined to assess anemia prevalence. Results: Of 320 patients with solid cancers, 245 (76.6%) were female and 75 (23.4%) were male. The median (interquartile range) age of 57 (45 ─ 66) years, range between 16 and 108 years. The types of cancer included were breast (29.1%), female genital tract (20.0%), colorectal (25.3%), head and neck (10.3%), urinary bladder (4.7%), prostate (5.0%), lung (2.5%), liver (2.2%) and lymphoma (0.9%). The prevalence of anemia at diagnosis of cancer was 44.1% across all cancer types. A higher anemia prevalence was noted in colorectal (n = 46/81, 56.8%) (p = 0.047). Conclusion: Patients with colorectal or female genital tract cancers had a higher anemia prevalence (56.8% and 43.8%, respectively) than did patients with other cancers.

30 December 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
MSMagdi Salih
Magdi Salih
AHAmjed A. Higgo
Amjed A. Higgo
EEEmad M. Eed
Emad M. Eed
Background/Aim: Breast cancer is the most common cancer in Sudan. The p16 protein plays a vital role in the regulation of the cell cycle. Patients and Methods: This study analysed the protein expression of p16 in 202 paraffin blocks from Sudanese women with breast cancer using immunohistochemistry. Results: This study included 168 (83.2%), 16 (7.9%), and 18 (8.9%) patients with invasive ductal carcinoma, invasive lobular carcinoma, and papillary carcinoma, respectively. There were 95 cases (47.0%) with grade III, 70 cases (34.6%) with grade II, and 23 cases (11.4%) with grade I breast cancer. The hormone receptor status was available for 119 of the cases, and 31 (15.3%), 25 (12.4%), and 63 (31.2%) cases were positive for oestrogen, progesterone, and HER2 receptors, respectively. Conclusion: p16 protein expression was associated with high histologic grade, lymph node metastasis, and poor prognosis. p16 protein expression may potentially be used as a prognostic marker.

18 May 2022 in Placenta
Verified
Journal Article
Closed access
MSMagdi Salih
Magdi Salih
LALobna E. Ali
Lobna E. Ali
EEEmad M. Eed
Emad M. Eed
ASAhmed Abu Siniyeh
Ahmed Abu Siniyeh